Ipsos Healthcare Rolls Out New Cancer Monitor

Ipsos Healthcare has launched a syndicated PD-L1 Testing Monitor, to measure and track awareness, perceptions, and detailed usage metrics around specific testing across all solid cancer types.

PD-L1 (programmed death-ligand 1 - also known as CD274) is a protein that plays a role in suppressing the immune system during events such as pregnancy and autoimmune disease. Launched to complement the firm's Solid Tumours MDx Monitor, Ipsos Healthcare says its new study offers a 'deep-dive' into the immune-oncology space.

The monitor starts with a panel of medical oncologists, pathologists and lab directors who complete a perceptual questionnaire, covering areas such as awareness and usage of PD-L1 testing by cancer type and histology, drivers for and barriers to PD-L1 testing, and awareness and perceptions of the various test kits. Then, oncologists and pathologists complete a number of records for actual, real-world patients and samples that have been recently tested for PD-L1 expression. Records, collected on an ongoing basis throughout the year, are designed to capture detailed information on the PD-L1 expression tests themselves, as well as the context in which they were conducted.

The monitor is currently available in the US with rollout to other markets planned. Ipsos says that due to the continuous data collection methodology and the focus on one specific biomarker, a 'large and robust' dataset will be possible.

Web site: www.ipsoshealthcare.com .